Early Access vs. Proven Efficacy: FDA’s Accelerated Approval Process
A recent JAMA article noted that only one-third of new drug approvals through the accelerated approval process by the FDA in the US or the conditional marketing authorization in the EU have shown therapeutic value. Many of these drugs are high cost, and this begs the question if we are spending our health care dollars appropriately. … Read More »
